809 related articles for article (PubMed ID: 30501974)
1. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
2. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
[TBL] [Abstract][Full Text] [Related]
3. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
4. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U; Harmer C; Yap B; Wadsley J; Clarke S; Moss L; Nicol A; Clark PM; Farnell K; McCready R; Smellie J; Franklyn JA; John R; Nutting CM; Newbold K; Lemon C; Gerrard G; Abdel-Hamid A; Hardman J; Macias E; Roques T; Whitaker S; Vijayan R; Alvarez P; Beare S; Forsyth S; Kadalayil L; Hackshaw A
N Engl J Med; 2012 May; 366(18):1674-85. PubMed ID: 22551128
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
8. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
9. High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.
Gray KD; Bannani S; Caillard C; Amanat S; Ullmann TM; Romanov P; Brunaud L; Beninato T; Fahey TJ; Mirallie E; Zarnegar R
Surgery; 2019 Jan; 165(1):37-43. PubMed ID: 30274732
[TBL] [Abstract][Full Text] [Related]
10. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients.
Rosario PW; Xavier AC
Am J Clin Oncol; 2012 Apr; 35(2):101-4. PubMed ID: 21297429
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of long-term combined treatment in follicular thyroid carcinoma].
Baranauskas Z; Valuckas KP; Tiskevicius S
Medicina (Kaunas); 2010; 46(4):268-74. PubMed ID: 20571295
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
[TBL] [Abstract][Full Text] [Related]
18. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
